ABOUT CYSTOTECH
Transforming bladder cancer care.
WHO WE ARE
Built by clinicians – for clinicians
Born in Aarhus, Denmark, the idea behind Cystotech emerged from hands-on clinical experience and the realities of everyday bladder cancer care.
Years of everyday clinical practice revealed how demanding bladder cancer assessment can be. Both for clinicians navigating complex real-time decisions and for patients facing repeated procedures, long-term surveillance, and ongoing uncertainty.
Driven by a desire to change status quo, clinicians, software engineers, and innovators joined forces around a shared mission: To bring meaningful innovation into everyday cystoscopy practice and improve bladder cancer care.
Cystotech is build around a shared mission:
To bring meaningful innovation into everyday cystoscopy practice and improve bladder cancer care.
From clinical insight to meaningful innovation
Rather than developing technology in isolation, Cystotech builds solutions shaped around the realities of everyday cystoscopy practice.
Every aspect of the product is designed with a deep understanding of the demands healthcare professionals face every day – from usability and workflow integration to the need for reliable real-time support in the clinical setting.
Our ambition is to help shape a future where intelligent clinical support becomes a natural part of everyday cystoscopy practice – empowering clinicians with technology that fits seamlessly into the way they already work.
2018 – 2021
Concept idea
Prospective real-world data collection. First proof-of-concept models trained on real-world procedure recordings.
2021
Company founded
Cystotech ApS incorporated in Aarhus. Seed round closed with a syndicate of Danish medtech investors.
2024-2025
Clinical evidence generation
RAISE01 retrospective non-inferiority clinical trial.
RAISE02 prospective non-inferiority RCT trial.
APRIL 2025
CE / MDR approval
Certification as MDR Class IIb Software as a Medical Device.
H1 2026
Commercial launch in Europe
First commercial sites across Europe.